AnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 240.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 114,939 shares of the biotechnology company's stock after purchasing an additional 81,195 shares during the period. JPMorgan Chase & Co. owned approximately 0.38% of AnaptysBio worth $1,522,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in shares of AnaptysBio by 8.4% during the fourth quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock worth $24,411,000 after buying an additional 143,584 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of AnaptysBio by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 465,401 shares of the biotechnology company's stock valued at $15,594,000 after purchasing an additional 13,336 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of AnaptysBio by 41.0% in the 4th quarter. Victory Capital Management Inc. now owns 334,450 shares of the biotechnology company's stock valued at $4,428,000 after purchasing an additional 97,200 shares during the last quarter. Jennison Associates LLC raised its stake in shares of AnaptysBio by 1.6% during the fourth quarter. Jennison Associates LLC now owns 269,131 shares of the biotechnology company's stock worth $3,563,000 after purchasing an additional 4,242 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of AnaptysBio by 3.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 166,054 shares of the biotechnology company's stock worth $2,199,000 after purchasing an additional 5,733 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Wedbush restated an "outperform" rating and set a $40.00 price objective on shares of AnaptysBio in a research report on Wednesday, February 12th. Wells Fargo & Company increased their price target on shares of AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. HC Wainwright restated a "neutral" rating and issued a $22.00 price objective on shares of AnaptysBio in a research report on Tuesday, March 4th. Johnson Rice reiterated a "buy" rating on shares of AnaptysBio in a research report on Wednesday, March 26th. Finally, Wolfe Research assumed coverage on AnaptysBio in a report on Tuesday, February 4th. They issued an "outperform" rating and a $25.00 price target for the company. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $33.63.

AnaptysBio Stock Performance

ANAB stock traded down $0.15 during midday trading on Tuesday, hitting $21.18. 346,034 shares of the stock were exchanged, compared to its average volume of 595,494. The stock's 50-day moving average price is $17.96 and its 200-day moving average price is $19.37. The stock has a market cap of $649.53 million, a price-to-earnings ratio of -3.48 and a beta of -0.09. AnaptysBio, Inc. has a fifty-two week low of $12.21 and a fifty-two week high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share for the quarter, beating analysts' consensus estimates of ($1.61) by $0.89. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The business had revenue of $43.11 million during the quarter, compared to analysts' expectations of $10.17 million. Research analysts anticipate that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio announced that its Board of Directors has initiated a stock repurchase plan on Monday, March 24th that allows the company to repurchase $75.00 million in outstanding shares. This repurchase authorization allows the biotechnology company to buy up to 13.1% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company's board of directors believes its shares are undervalued.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.